Welcome to BioSeeker Group!

A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market

Additional Information

Published Date Nov 17, 2010
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 777
PDF Fact Sheet View Fact Sheet for the report A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market.

    To find out more about A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. BioSeeker has applied its unique drug assessment methodology to stratify the melanoma pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of melanoma drugs is split between the 55% which have unique drug target strategies and the other part which have head-to-head target competing melanoma drugs in 32 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the melanoma drugs in general. Contributing to this fact is heavily utilized drug target strategies like: IFNAR2, BRAF and TUBB.

* Nine out of ten drug target strategies in Phase II development are new to melanoma drugs and at the same time the greatest numbers of new target strategies are found in Phase II (27%) and Phase I development (19%).

* Small molecules, antibodies and proteins are the dominating compound strategies of melanoma drugs, which represent almost three quarters of the entire pipeline. Cell therapy based melanoma drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of melanoma drugs.

* The highest number of described drug target strategies of melanoma drugs belongs to Pfizer, Novartis, Hoffmann-La Roche and Bristol-Myers Squibb.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any melanoma drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 18
4.2 List of Tables 18
5 Introduction 25
5.1 The Scope of this Report 25
5.2 Definitions 28
5.3 Abbreviations 28
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment 29
6.1 Drug Repositioning in Oncology 29
6.2 Introduction to Targets of Melanoma Drugs 30
6.2.1 Carboxy-lyase Activity Targets 36
6.2.2 Carboxypeptidase Activity Targets 37
6.2.3 Catalytic Activity Targets 39
6.2.4 Cell Adhesion Molecule Activity Targets 44
6.2.5 Chaperone Activity Targets 49
6.2.6 Chemokine Activity Targets 52
6.2.7 Cofactor Binding Targets 54
6.2.8 Complement Activity Targets 56
6.2.9 Cysteine-type Peptidase Activity Targets 58
6.2.10 Cytokine Activity Targets 61
6.2.11 DNA Binding Targets 72
6.2.12 DNA Repair Protein Targets 73
6.2.13 DNA Topoisomerase Activity Targets 76
6.2.14 DNA-directed DNA Polymerase Activity Targets 79
6.2.15 DNA-methyltransferase Activity Targets 85
6.2.16 Extracellular Ligand-gated Ion Channel Activity Targets 86
6.2.17 Extracellular Matrix Structural Constituent Targets 87
6.2.18 G-protein Coupled Receptor Activity Targets 90
6.2.19 Growth Factor Activity Targets 98
6.2.20 GTPase Activity Targets 103
6.2.21 Hydrolase Activity Targets 105
6.2.22 Isomerase Activity Targets 106
6.2.23 Kinase Activity Targets 107
6.2.24 Kinase Regulator Activity Targets 118
6.2.25 Ligase Activity Targets 120
6.2.26 Lipase Activity Targets 126
6.2.27 Metallopeptidase Activity Targets 127
6.2.28 MHC Class I Receptor Activity Targets 128
6.2.29 Molecular Function Unknown Targets 129
6.2.30 Motor Activity Targets 140
6.2.31 Oxidoreductase Activity Targets 142
6.2.32 Peptide Hormone Targets 147
6.2.33 Protein Binding Targets 148
6.2.34 Protein Serine/Threonine Kinase Activity Targets 153
6.2.35 Protein Threonine/Tyrosine Kinase Activity Targets 169
6.2.36 Protein Tyrosine Phosphatase Activity Targets 174
6.2.37 Protein-tyrosine Kinase Activity Targets 182
6.2.38 Receptor Activity Targets 188
6.2.39 Receptor Binding Targets 212
6.2.40 Receptor Signaling Complex Scaffold Activity Targets 216
6.2.41 RNA-directed DNA Polymerase Activity Targets 219
6.2.42 Serine-type Peptidase Activity Targets 220
6.2.43 Structural Constituent of Cytoskeleton Targets 221
6.2.44 Superoxide Dismutase Activity Targets 222
6.2.45 T Cell Receptor Activity Targets 226
6.2.46 Transcription Factor Activity Targets 228
6.2.47 Transcription Regulator Activity Targets 244
6.2.48 Transferase Activity Targets 247
6.2.49 Translation Regulator Activity Targets 249
6.2.50 Transmembrane Receptor Activity Targets 251
6.2.51 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 259
6.2.52 Transporter Activity Targets 295
6.2.53 Ubiquitin-specific Protease Activity Targets 296
6.2.54 Other Targets 297
6.3 The Cancer Genome Project and Targets of Melanoma Drugs 299
6.3.1 Targets of Melanoma Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 299
6.4 Structure-based Drug Design in Melanoma Therapeutics is Stimulated by Available Structure Data on Biological Targets 304
6.5 Target-Target Interactions among Identified Targets of Melanoma Drugs 307
6.6 The Drug-Target Competitive Landscape 312
6.7 Protein Expression Levels of Identified Targets of Melanoma Drugs 316
6.8 Pathway Assessment of Melanoma Drugs 320
6.8.1 Tools for Analysis of Cancer Pathways 321
6.8.2 Pathway Assessment 322
7 Emerging New Products to Established Ones: Drug Target Strategies of Melanoma Drugs by their Highest Stage of Development 364
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Melanoma Drugs 366
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Melanoma Drugs 367
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Melanoma Drugs 368
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Melanoma Drugs 371
7.5 Preclinical Development: New and Unique Drug Target Strategies of Melanoma Drugs 374
7.6 No Development Data: New and Unique Drug Target Strategies of Melanoma Drugs 376
7.7 Drug Target Strategies of Suspended, Discontinued or Terminated Melanoma Drugs 377
7.8 Target Strategy Development Profiles of Melanoma Drugs 380
7.8.1 Marketed 383
7.8.2 Registered 387
7.8.3 Pre-registration 388
7.8.4 Phase III 390
7.8.5 Phase II 396
7.8.6 Phase I 447
7.8.7 Preclinical 476
7.8.8 No Data 494
7.8.9 Suspended 501
7.8.10 Discontinued 503
7.8.11 Ceased 506
7.9 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 535
8 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy 539
8.1 Small Molecules 541
8.1.1 Background 541
8.1.2 Target Strategies of Small Molecule Drugs 542
8.2 Peptide & Protein Drugs 549
8.2.1 Background 549
8.2.2 Target Strategies of Peptide and Protein Drugs 550
8.3 Antibodies and Antibody-like Structures 555
8.3.1 Background 555
8.3.2 Target Strategies of Antibody Drugs 555
8.4 Nucleic Acid Therapies 558
8.4.1 Background 558
8.4.2 Target Strategies of Nucleic Acid Drugs 559
8.5 Cell & Gene Therapy 561
8.5.1 Background 561
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 562
8.6 Drug Delivery and Nanotechnology 567
8.6.1 Background 567
8.6.2 Target Strategies of Reformulated Drugs 567
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 569
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Investigator 575
9.1 Competitive Fall-Out Assessment 575
9.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 577
9.3 3SBio 578
9.4 Abbott 579
9.5 Abiogen 581
9.6 Abraxis BioScience 582
9.7 Actelion 583
9.8 Adherex 584
9.9 Advanced Life Sciences 585
9.10 Advaxis 586
9.11 Aeterna Zentaris 587
9.12 Alnylam 588
9.13 Altor BioScience 589
9.14 Ambit Biosciences 590
9.15 AngioChem 592
9.16 Antisense Pharma 593
9.17 Antisoma 594
9.18 Aphios 595
9.19 ApopLogic Pharmaceuticals 596
9.20 Apotex 597
9.21 Ariad 598
9.22 ArQule 599
9.23 Array BioPharma 601
9.24 Astellas 603
9.25 Astex Therapeutics 604
9.26 AstraZeneca 605
9.27 Attenuon 607
9.28 Bayer 608
9.29 Bio-Medisinsk Innovasjon 611
9.30 BioAlliance Pharma 612
9.31 Biogen Idec 613
9.32 Biokine Therapeutics 614
9.33 BioNumerik 615
9.34 Biosceptre 616
9.35 Biotecnol 617
9.36 BioVex 618
9.37 Boehringer Ingelheim 620
9.38 Bristol-Myers Squibb 621
9.39 Cancer Research Technology 624
9.40 CDG Therapeutics 625
9.41 Cell Genesys 626
9.42 Celldex Therapeutics 627
9.43 Celtic Pharma 629
9.44 CJ Corp 630
9.45 Clavis Pharma 631
9.46 Cosmo Pharmaceuticals 632
9.47 CSL 633
9.48 CytImmune Sciences 634
9.49 Cytokinetics 635
9.50 Daewoong 636
9.51 Dara Biosciences 637
9.52 Deciphera Pharmaceuticals 638
9.53 DNAVEC 640
9.54 Dong-A 641
9.55 Eisai 643
9.56 Eli Lilly 645
9.57 EntreMed 648
9.58 Enzon 650
9.59 EpiCept 651
9.60 Exelixis 653
9.61 Facet Biotech 655
9.62 Flamel Technologies 656
9.63 Genta 657
9.64 GenVec 658
9.65 Genzyme 659
9.66 GlaxoSmithKline 661
9.67 Hemispherx Biopharma 663
9.68 Hoffmann-La Roche 664
9.69 Ichor Medical Systems 668
9.70 Idera Pharmaceuticals 669
9.71 Immunocore 670
9.72 ImmunoGen 672
9.73 Immutep 673
9.74 Infinity Pharmaceuticals 674
9.75 Innate Pharma 675
9.76 Inotek 677
9.77 Inovio 679
9.78 Intrexon 681
9.79 Introgen Therapeutics 682
9.80 Ipsen 683
9.81 Jennerex Biotherapeutics 684
9.82 Johnson & Johnson 685
9.83 Kalypsys 687
9.84 Karyon-CTT 688
9.85 Kiadis 689
9.86 LG Life Sciences 690
9.87 Mannkind 691
9.88 MediGene 693
9.89 Medisyn Technologies 695
9.90 Merck KGaA 696
9.91 Mitsubishi Tanabe Pharma 698
9.92 Mochida 699
9.93 Mojave Therapeutics 700
9.94 MolMed 701
9.95 Mologen 702
9.96 Non-industrial Sources 704
9.97 Novartis 706
9.98 Novogen 711
9.99 Oncalis 712
9.100 OSI Pharmaceuticals 713
9.101 Oxford BioMedica 714
9.102 PBL Therapeutics 716
9.103 Pfizer 717
9.104 PharmaMar 722
9.105 PhiloGene 724
9.106 Piramal 725
9.107 Plexxikon 726
9.108 Progen 727
9.109 Reata Pharmaceuticals 728
9.110 Regulon 729
9.111 Sanofi-Aventis 730
9.112 Santaris Pharma 732
9.113 Sareum 733
9.114 Scancell 734
9.115 SciClone Pharmaceuticals 735
9.116 Seattle Genetics 736
9.117 Shire 737
9.118 Simcere Pharmaceuticals 738
9.119 Solbec Pharmaceuticals 739
9.120 Spirogen 740
9.121 SuperGen 741
9.122 Swedish Orphan Biovitrum 743
9.123 Takeda 744
9.124 Targa Therapeutics 746
9.125 Targepeutics 747
9.126 Thallion Pharmaceuticals 748
9.127 Therion Biologics 749
9.128 TopoTarget 750
9.129 Tracon Pharmaceuticals 752
9.130 Transgene 753
9.131 VaxOnco 755
9.132 VBL Therapeutics 756
9.133 Vectura 757
9.134 Vical 758
9.135 VioQuest 760
9.136 ViroTarg 762
9.137 Xerion 763
9.138 York Pharma 765
9.139 ZymoGenetics 766
10 Disclaimer 767
11 Drug Index 768
12 Company Index 773

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Melanoma Drugs 311
Figure 2: The Drug-Target Competitive Landscape of Melanoma Drugs - Large Cluster 313
Figure 3: The Drug-Target Competitive Landscape Melanoma Drugs - Smaller Clusters 314
Figure 4: Head-to-Head Targeting Competitive Landscape of Melanoma Drugs 315
Figure 5: Distribution of Compound Strategies among Melanoma Drugs 569
Figure 6: Primary Sub-cellular Localization of Drug Targets 570

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Melanoma Drug Pipeline by Stage of Development 25
Table 3: Head to Head Target Competition among Melanoma Drugs 25
Table 4: Overview of Drug Target Strategy Themes 30
Table 5: Terminally Ceased Targets of Melanoma Drugs 31
Table 6: Official Gene Name to Target Profle 32
Table 7: Targets of Melanoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 300
Table 8: Identity of Melanoma Drug Targets with Available Biological Structures 304
Table 9: Number of Target-Target Interactions among Targets of Melanoma Drugs 307
Table 10: Available Protein Expression Profiles of Melanoma Drugs Targets 316
Table 11: Pathway Summary 322
Table 12: Drug Targets without any Identified Assigned Pathways 322
Table 13: Pathway Profiles According to BioCarta of Melanoma Drug Targets 324
Table 14: Pathway Profiles According to KEGG of Melanoma Drug Targets 340
Table 15: Pathway Profiles According to NetPath of Melanoma Drug Targets 360
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 364
Table 17: Top Competitive Target Strategies of Melanoma Drugs 365
Table 18: New and Unique Target Strategies of Pre-registration to Marketed Melanoma Drugs 366
Table 19: The Competition Through Close Mechanistic Approximation Between Melanoma Drugs in Pre-registration to being Marketed 366
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Melanoma Drugs 367
Table 21: New and Unique Target Strategies in Phase II Clinical Development of Melanoma Drugs 368
Table 22: The Competition Through Close Mechanistic Approximation Between Phase II Melanoma Drugs 370
Table 23: New and Unique Target Strategies in Phase I Clinical Development of Melanoma Drugs 371
Table 24: The Competition Through Close Mechanistic Approximation Between Phase I Melanoma Drugs 372
Table 25: New and Unique Target Strategies in Preclinical Development of Melanoma Drugs 374
Table 26: The Competition Through Close Mechanistic Approximation Between Preclinical Melanoma Drugs 375
Table 27: New and Unique Target Strategies in Unknown Developmental Stage of Melanoma Drugs 376
Table 28: Target Strategies of Suspended, Discontinued and Terminated Melanoma Drugs 377
Table 29: Connecting Target Strategy with Its Identification Number 380
Table 30: The Competition Through Close Mechanistic Approximation Among Melanoma Drugs 535
Table 31: Overview of Compound Strategy Competition Among Melanoma Drugs 540
Table 32: Overview of the Competitive Landscape of Small Molecule Based Melanoma Drugs 542
Table 33: Competitive Comparison of Target Strategies of Small Molecule Melanoma Drugs 543
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Melanoma Drugs 545
Table 35: Overview of the Competitive Landscape of Peptide Based Melanoma Drugs 550
Table 36: Competitive Comparison of Target Strategies of Peptide Based Melanoma Drugs 551
Table 37: Pursued Target Strategies of Peptide Based Melanoma Drugs 551
Table 38: Overview of the Competitive Landscape of Protein Based Melanoma Drugs 552
Table 39: Competitive Comparison of Target Strategies of Protein Based Melanoma Drugs 553
Table 40: Pursued Target Strategies of Protein Based Melanoma Drugs 553
Table 41: Overview of the Competitive Landscape of Antibody Based Melanoma Drugs 555
Table 42: Competitive Comparison of Target Strategies of Antibody Based Melanoma Drugs 556
Table 43: Pursued Target Strategies of Antibody Based Melanoma Drugs 557
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Melanoma Drugs 559
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Melanoma Drugs 560
Table 46: Pursued Target Strategies of Nucleic Acid Based Melanoma Drugs 560
Table 47: Potential Forms of Cell Therapy 561
Table 48: Vectors in Gene Therapy 562
Table 49: Overview of the Competitive Landscape of Cell Therapy Based Melanoma Drugs 562
Table 50: Pursued Target Strategies of Cell Therapy Based Melanoma Drugs 563
Table 51: Overview of the Competitive Landscape of Gene Therapy Based Melanoma Drugs 564
Table 52: Competitive Comparison of Target Strategies of Gene Therapy Based Melanoma Drugs 565
Table 53: Pursued Target Strategies of Gene Therapy Based Melanoma Drugs 565
Table 54:Overview of the Competitive Landscape of Reformulated Melanoma Drugs 567
Table 55: Competitive Comparison of Target Strategies of Reformulated Melanoma Drugs 568
Table 56: Pursued Target Strategies of Reformulated Melanoma Drugs 568
Table 57: Compound Strategies based on Sub-Cellular Localization of Melanoma Drug Targets 570
Table 58: Example of a Competitive Fall-Out Table (BRAF) 576
Table 59: Summary Table of Corporate Changes in the Competitive Landscape of Melanoma Drug Development 577
Table 60: 3SBio’s Included Melanoma Pipeline and Competitive Fall-Out 578
Table 61: Abbott’s Included Melanoma Pipeline and Competitive Fall-Out 579
Table 62: Abiogen’s Included Melanoma Pipeline and Competitive Fall-Out 581
Table 63: Abraxis BioScience’s Included Melanoma Pipeline and Competitive Fall-Out 582
Table 64: Actelion’s Included Melanoma Pipeline and Competitive Fall-Out 583
Table 65: Adherex’s Included Melanoma Pipeline and Competitive Fall-Out 584
Table 66: Advanced Life Sciences’ Included Melanoma Pipeline and Competitive Fall-Out 585
Table 67: Advaxis’ Included Melanoma Pipeline and Competitive Fall-Out 586
Table 68: Aeterna Zentaris’ Included Melanoma Pipeline and Competitive Fall-Out 587
Table 69: Alnylam’s Included Melanoma Pipeline and Competitive Fall-Out 588
Table 70: Altor BioScience’s Included Melanoma Pipeline and Competitive Fall-Out 589
Table 71: Ambit Biosciences’ Included Melanoma Pipeline and Competitive Fall-Out 590
Table 72: AngioChem’s Included Melanoma Pipeline and Competitive Fall-Out 592
Table 73: Antisense Pharma’s Included Melanoma Pipeline and Competitive Fall-Out 593
Table 74: Antisoma’s Included Melanoma Pipeline and Competitive Fall-Out 594
Table 75: Aphios’ Included Melanoma Pipeline and Competitive Fall-Out 595
Table 76: ApopLogic Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 596
Table 77: Apotex’s Included Melanoma Pipeline and Competitive Fall-Out 597
Table 78: Ariad’s Included Melanoma Pipeline and Competitive Fall-Out 598
Table 79: ArQule’s Included Melanoma Pipeline and Competitive Fall-Out 599
Table 80: Array BioPharma’s Included Melanoma Pipeline and Competitive Fall-Out 601
Table 81: Astellas’ Included Melanoma Pipeline and Competitive Fall-Out 603
Table 82: Astex Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 604
Table 83: AstraZeneca’s Included Melanoma Pipeline and Competitive Fall-Out 605
Table 84: Attenuon’s Included Melanoma Pipeline and Competitive Fall-Out 607
Table 85: Bayer’s Included Melanoma Pipeline and Competitive Fall-Out 608
Table 86: Bio-Medisinsk Innovasjon’s Included Melanoma Pipeline and Competitive Fall-Out 611
Table 87: BioAlliance Pharma’s Included Melanoma Pipeline and Competitive Fall-Out 612
Table 88: Biogen Idec’s Included Melanoma Pipeline and Competitive Fall-Out 613
Table 89: Biokine Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 614
Table 90: BioNumerik’s Included Melanoma Pipeline and Competitive Fall-Out 615
Table 91: Biosceptre’s Included Melanoma Pipeline and Competitive Fall-Out 616
Table 92: Biotecnol’s Included Melanoma Pipeline and Competitive Fall-Out 617
Table 93: BioVex’s Included Melanoma Pipeline and Competitive Fall-Out 618
Table 94: Boehringer Ingelheim’s Included Melanoma Pipeline and Competitive Fall-Out 620
Table 95: Bristol-Myers Squibb’s Included Melanoma Pipeline and Competitive Fall-Out 621
Table 96: Cancer Research Technology’s Included Melanoma Pipeline and Competitive Fall-Out 624
Table 97: CDG Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 625
Table 98: Cell Genesys’ Included Melanoma Pipeline and Competitive Fall-Out 626
Table 99: Celldex Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 627
Table 100: Celtic Pharma’s Included Melanoma Pipeline and Competitive Fall-Out 629
Table 101: CJ Corp’s Included Melanoma Pipeline and Competitive Fall-Out 630
Table 102: Clavis Pharma’s Included Melanoma Pipeline and Competitive Fall-Out 631
Table 103: Cosmo Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 632
Table 104: CSL’s Included Melanoma Pipeline and Competitive Fall-Out 633
Table 105: CytImmune Sciences’ Included Melanoma Pipeline and Competitive Fall-Out 634
Table 106: Cytokinetics’ Included Melanoma Pipeline and Competitive Fall-Out 635
Table 107: Daewoong’s Included Melanoma Pipeline and Competitive Fall-Out 636
Table 108: Dara Biosciences’ Included Melanoma Pipeline and Competitive Fall-Out 637
Table 109: Deciphera Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 638
Table 110: DNAVEC’s Included Melanoma Pipeline and Competitive Fall-Out 640
Table 111: Dong-A’s Included Melanoma Pipeline and Competitive Fall-Out 641
Table 112: Eisai’s Included Melanoma Pipeline and Competitive Fall-Out 643
Table 113: Eli Lilly’s Included Melanoma Pipeline and Competitive Fall-Out 645
Table 114: EntreMed’s Included Melanoma Pipeline and Competitive Fall-Out 648
Table 115: Enzon’s Included Melanoma Pipeline and Competitive Fall-Out 650
Table 116: EpiCept’s Included Melanoma Pipeline and Competitive Fall-Out 651
Table 117: Exelixis’ Included Melanoma Pipeline and Competitive Fall-Out 653
Table 118: Facet Biotech’s Included Melanoma Pipeline and Competitive Fall-Out 655
Table 119: Flamel Technologies’ Included Melanoma Pipeline and Competitive Fall-Out 656
Table 120: Genta’s Included Melanoma Pipeline and Competitive Fall-Out 657
Table 121: GenVec’s Included Melanoma Pipeline and Competitive Fall-Out 658
Table 122: Genzyme’s Included Melanoma Pipeline and Competitive Fall-Out 659
Table 123: GlaxoSmithKline’s Included Melanoma Pipeline and Competitive Fall-Out 661
Table 124: Hemispherx Biopharma’s Included Melanoma Pipeline and Competitive Fall-Out 663
Table 125: Hoffmann-La Roche’s Included Melanoma Pipeline and Competitive Fall-Out 664
Table 126: Ichor Medical Systems’ Included Melanoma Pipeline and Competitive Fall-Out 668
Table 127: Idera Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 669
Table 128: Immunocore’s Included Melanoma Pipeline and Competitive Fall-Out 670
Table 129: ImmunoGen’s Included Melanoma Pipeline and Competitive Fall-Out 672
Table 130: Immutep’s Included Melanoma Pipeline and Competitive Fall-Out 673
Table 131: Infinity Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 674
Table 132: Innate Pharma’s Included Melanoma Pipeline and Competitive Fall-Out 675
Table 133: Inotek’s Included Melanoma Pipeline and Competitive Fall-Out 677
Table 134: Inovio’s Included Melanoma Pipeline and Competitive Fall-Out 679
Table 135: Intrexon’s Included Melanoma Pipeline and Competitive Fall-Out 681
Table 136: Introgen Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 682
Table 137: Ipsen’s Included Melanoma Pipeline and Competitive Fall-Out 683
Table 138: Jennerex Biotherapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 684
Table 139: Johnson & Johnson’s Included Melanoma Pipeline and Competitive Fall-Out 685
Table 140: Kalypsys’ Included Melanoma Pipeline and Competitive Fall-Out 687
Table 141: Karyon-CTT’s Included Melanoma Pipeline and Competitive Fall-Out 688
Table 142: Kiadis’ Included Melanoma Pipeline and Competitive Fall-Out 689
Table 143: LG Life Sciences’ Included Melanoma Pipeline and Competitive Fall-Out 690
Table 144: Mannkind’s Included Melanoma Pipeline and Competitive Fall-Out 691
Table 145: MediGene’s Included Melanoma Pipeline and Competitive Fall-Out 693
Table 146: Medisyn Technologies’ Included Melanoma Pipeline and Competitive Fall-Out 695
Table 147: Merck KGaA’s Included Melanoma Pipeline and Competitive Fall-Out 696
Table 148: Mitsubishi Tanabe Pharma’s Included Melanoma Pipeline and Competitive Fall-Out 698
Table 149: Mochida’s Included Melanoma Pipeline and Competitive Fall-Out 699
Table 150: Mojave Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 700
Table 151: MolMed’s Included Melanoma Pipeline and Competitive Fall-Out 701
Table 152: Mologen’s Included Melanoma Pipeline and Competitive Fall-Out 702
Table 153: Non-industrial Sources’ Included Melanoma Pipeline and Competitive Fall-Out 704
Table 154: Novartis’ Included Melanoma Pipeline and Competitive Fall-Out 706
Table 155: Novogen’s Included Melanoma Pipeline and Competitive Fall-Out 711
Table 156: Oncalis’ Included Melanoma Pipeline and Competitive Fall-Out 712
Table 157: OSI Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 713
Table 158: Oxford BioMedica’s Included Melanoma Pipeline and Competitive Fall-Out 714
Table 159: PBL Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 716
Table 160: Pfizer’s Included Melanoma Pipeline and Competitive Fall-Out 717
Table 161: PharmaMar’s Included Melanoma Pipeline and Competitive Fall-Out 722
Table 162: PhiloGene’s Included Melanoma Pipeline and Competitive Fall-Out 724
Table 163: Piramal’s Included Melanoma Pipeline and Competitive Fall-Out 725
Table 164: Plexxikon’s Included Melanoma Pipeline and Competitive Fall-Out 726
Table 165: Progen’s Included Melanoma Pipeline and Competitive Fall-Out 727
Table 166: Reata Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 728
Table 167: Regulon’s Included Melanoma Pipeline and Competitive Fall-Out 729
Table 168: Sanofi-Aventis’ Included Melanoma Pipeline and Competitive Fall-Out 730
Table 169: Santaris Pharma’s Included Melanoma Pipeline and Competitive Fall-Out 732
Table 170: Sareum’s Included Melanoma Pipeline and Competitive Fall-Out 733
Table 171: Scancell’s Included Melanoma Pipeline and Competitive Fall-Out 734
Table 172: SciClone Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 735
Table 173: Seattle Genetics’ Included Melanoma Pipeline and Competitive Fall-Out 736
Table 174: Shire’s Included Melanoma Pipeline and Competitive Fall-Out 737
Table 175: Simcere Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 738
Table 176: Solbec Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 739
Table 177: Spirogen’s Included Melanoma Pipeline and Competitive Fall-Out 740
Table 178: SuperGen’s Included Melanoma Pipeline and Competitive Fall-Out 741
Table 179: Swedish Orphan Biovitrum’s Included Melanoma Pipeline and Competitive Fall-Out 743
Table 180: Takeda’s Included Melanoma Pipeline and Competitive Fall-Out 744
Table 181: Targa Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 746
Table 182: Targepeutics’ Included Melanoma Pipeline and Competitive Fall-Out 747
Table 183: Thallion Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 748
Table 184: Therion Biologics’ Included Melanoma Pipeline and Competitive Fall-Out 749
Table 185: TopoTarget’s Included Melanoma Pipeline and Competitive Fall-Out 750
Table 186: Tracon Pharmaceuticals’ Included Melanoma Pipeline and Competitive Fall-Out 752
Table 187: Transgene’s Included Melanoma Pipeline and Competitive Fall-Out 753
Table 188: VaxOnco’s Included Melanoma Pipeline and Competitive Fall-Out 755
Table 189: VBL Therapeutics’ Included Melanoma Pipeline and Competitive Fall-Out 756
Table 190: Vectura’s Included Melanoma Pipeline and Competitive Fall-Out 757
Table 191: Vical’s Included Melanoma Pipeline and Competitive Fall-Out 758
Table 192: VioQuest’s Included Melanoma Pipeline and Competitive Fall-Out 760
Table 193: ViroTarg’s Included Melanoma Pipeline and Competitive Fall-Out 762
Table 194: Xerion’s Included Melanoma Pipeline and Competitive Fall-Out 763
Table 195: York Pharma’s Included Melanoma Pipeline and Competitive Fall-Out 765
Table 196: ZymoGenetics’ Included Melanoma Pipeline and Competitive Fall-Out 766

This report includes 138 companies plus their collaborators:
3SBio
Abbott
Abiogen
Abraxis BioScience
Actelion
Adherex
Advanced Life Sciences
Advaxis
Aeterna Zentaris
Alnylam
Altor BioScience
Ambit Biosciences
AngioChem
Antisense Pharma
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Ariad
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Bayer
BioAlliance Pharma
Biogen Idec
Biokine Therapeutics
Bio-Medisinsk Innovasjon
BioNumerik
Biosceptre
Biotecnol
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
Cancer Research Technology
CDG Therapeutics
Cell Genesys
Celldex Therapeutics
Celtic Pharma
CJ Corp
Clavis Pharma
Cosmo Pharmaceuticals
CSL
CytImmune Sciences
Cytokinetics
Daewoong
Dara Biosciences
Deciphera Pharmaceuticals
DNAVEC
Dong-A
Eisai
Eli Lilly
EntreMed
Enzon
EpiCept
Exelixis
Facet Biotech
Flamel Technologies
Genta
GenVec
Genzyme
GlaxoSmithKline
Hemispherx Biopharma
Hoffmann-La Roche
Ichor Medical Systems
Idera Pharmaceuticals
Immunocore
ImmunoGen
Immutep
Infinity Pharmaceuticals
Innate Pharma
Inotek
Inovio
Intrexon
Introgen Therapeutics
Ipsen
Jennerex Biotherapeutics
Johnson & Johnson
Kalypsys
Karyon-CTT
Kiadis
LG Life Sciences
Mannkind
MediGene
Medisyn Technologies
Merck KGaA
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Non-industrial source
Novartis
Novogen
Oncalis
OSI Pharmaceuticals
Oxford BioMedica
PBL Therapeutics
Pfizer
PharmaMar
PhiloGene
Piramal
Plexxikon
Progen
Reata Pharmaceuticals
Regulon
Sanofi-Aventis
Santaris Pharma
Sareum
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spirogen
SuperGen
Swedish Orphan Biovitrum
Takeda
Targa Therapeutics
Targepeutics
Thallion Pharmaceuticals
Therion Biologics
TopoTarget
Tracon Pharmaceuticals
Transgene
VaxOnco
VBL Therapeutics
Vectura
Vical
VioQuest
ViroTarg
Xerion
York Pharma
ZymoGenetics
This report includes 218 cancer drugs. From Ceased to Marketed.
AG-14699
agatolimod
aldesleukin
ALT-801
APO-866
astuprotimut-r
axitinib
bardoxolone methyl
belinostat
bevacizumab
BMS-663513
bortezomib
bosentan
cositecan
dasatinib
decitabine
denenicokin
dovitinib lactate
EMD-273063
endostatin
entinostat
epirubicin
everolimus
Exherin
fresolimumab
gefitinib
glembatumumab
golnerminogene pradenovec
GT-111
GV-1001
histamine dihydrochloride
imatinib mesilate
IMP-321
INGN-241
interferon-alpha
interferon-alpha2
interferon-alpha2a
interferon-alpha2b
interferon-beta
interleukin-2, 2nd-generation
intetumumab
IPH-1101
ipilimumab
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
LipoVIL12
MDX-1106
MetXia
MGN-1601
MKC-1106-MT
oblimersen sodium
OncoVEX GM-CSF
P-276-00
peginterferon alfa-2b
perifosine
plitidepsin
PLX-4032
ramucirumab
retaspimycin
sagopilone
sargramostim
selumetinib
sodium stibogluconate
sunitinib malate
thymalfasin
topotecan
trabedersen
tremelimumab
velimogene aliplasmid
veliparib
volociximab
YM-155

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market.
    To find out more about A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications. Learn More


A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. Learn More

Other selected research from the 'Oncology' category:


Cancer Vaccines Fantasy or Future?
In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements. Learn More


Triple Analysis: Leukemia, Pancreatic Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Learn More